DrugPatentWatch Database Preview
Drugs in Development Information for Ipatasertib
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug Ipatasertib?
Ipatasertib is an investigational drug.
There have been 21 clinical trials for Ipatasertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 18th 2019.
The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Massachusetts General Hospital.
There are twenty-four US patents protecting this investigational drug and three hundred and eighty-one international patents.
Summary for Ipatasertib
| US Patents | 24 |
| International Patents | 381 |
| US Patent Applications | 49 |
| WIPO Patent Applications | 29 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2019-12-18) |
| Vendors | 45 |
Recent Clinical Trials for Ipatasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer. | Hoffmann-La Roche | Phase 3 |
| A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer | Hoffmann-La Roche | Phase 3 |
| AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) | Genentech, Inc. | Phase 1 |
Clinical Trial Summary for Ipatasertib
Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib
US Patents for Ipatasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ipatasertib | Start Trial | Polymeric nanoparticles and methods of making and using same | Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY) | Start Trial |
| Ipatasertib | Start Trial | Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use | GENENTECH, INC. (South San Francisco, CA) | Start Trial |
| Ipatasertib | Start Trial | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | Array BioPharma Inc. (Boulder, CO) Covenentech, Inc. (South San Francisco, CA) | Start Trial |
| Ipatasertib | Start Trial | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | Array Biopharma, Inc. (Boulder, CO) Genentech, Inc. (South San Francisco, CA) | Start Trial |
| Ipatasertib | Start Trial | Combinations of AKT inhibitor compounds and vemurafenib, and methods of use | Genentech, Inc. (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ipatasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ipatasertib | European Patent Office | 3119395 | 2034-03-17 | Start Trial |
| Ipatasertib | World Intellectual Property Organization (WIPO) | 2015142605 | 2034-03-17 | Start Trial |
| Ipatasertib | Australia | 2012236135 | 2031-04-01 | Start Trial |
| Ipatasertib | Australia | 2012236138 | 2031-04-01 | Start Trial |
| Ipatasertib | Australia | 2012236144 | 2031-04-01 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
